The Experts below are selected from a list of 1050 Experts worldwide ranked by ideXlab platform
Melvin M Grumbach - One of the best experts on this subject based on the ideXlab platform.
-
massive virginal Breast Hypertrophy as a cause of recurrent humoral hypercalcemia due to parathyroid hormone related protein pthrp secretion
Pediatric Research, 1993Co-Authors: Floyd Barry, Felix A Conte, Melvin M GrumbachAbstract:Humoral hypercalcemia associated with certain neoplasms is caused by their secretion of a parathyroid-like 16-18 kd peptide, PTHrP. PTHrP also is expressed by keratinocytes, placenta, fetal parathyroids, and lactating mouse mammary tissue. We report a 15 y old female who presented with massive virginal Breast Hypertrophy and symptoms of urinary frequency, fatigue, and personality changes attributable to hypercalcemia. At 13 1/2 y she had a successful liver transplant for α1-anti-trypsin deficiency. This was followed by rapid Breast growth; 6 months later she had menarche and then regular menses. At 15 y symptomatic hypercalcemia was documented -serum Ca 16 mg/dl, P 2.7 mg/dl, alk phosphatase 151 U/l, PTH 5 pg/ml (n=10-65), and PTHrP 9.4 pmol/L (n=<1.5); 1,25(OH)2D 28 pg/ml (20-76) unlike the usually elevated level with PTH excess. The hypercalcemia responded promptly to saline diuresis. Imaging studies failed to show a parathyroid abnormality or tumor. She had three subsequent episodes of symptomatic hypercalcumin 4 - 5 days prior to menses; PTHrP levels were undetectable between episodes. Following an extensive reduction mammoplasty, the hypercalcemia has not recurred. Studies of PTHrP mRNA in the tissue are in progress. In summary, benign Breast Hypertrophy can cause secretion of PTHrP which results in hypercalcomia. The cyclical occurrence and its temporal relationship to the menstrual cycle suggests that changes in circulating ovarian sex steroids may have affected PTHrP synthesis.
-
MASSIVE VIRGINAL Breast Hypertrophy AS A CAUSE OF RECURRENT HUMORAL HYPERCALCEMIA DUE TO PARATHYROID HORMONE-RELATED PROTEIN (PTHrP) SECRETION
Pediatric Research, 1993Co-Authors: Floyd Barry, Felix A Conte, Melvin M GrumbachAbstract:Humoral hypercalcemia associated with certain neoplasms is caused by their secretion of a parathyroid-like 16-18 kd peptide, PTHrP. PTHrP also is expressed by keratinocytes, placenta, fetal parathyroids, and lactating mouse mammary tissue. We report a 15 y old female who presented with massive virginal Breast Hypertrophy and symptoms of urinary frequency, fatigue, and personality changes attributable to hypercalcemia. At 13 1/2 y she had a successful liver transplant for α1-anti-trypsin deficiency. This was followed by rapid Breast growth; 6 months later she had menarche and then regular menses. At 15 y symptomatic hypercalcemia was documented -serum Ca 16 mg/dl, P 2.7 mg/dl, alk phosphatase 151 U/l, PTH 5 pg/ml (n=10-65), and PTHrP 9.4 pmol/L (n=
Lydia Masako Ferreira - One of the best experts on this subject based on the ideXlab platform.
-
Outcomes analysis of Breast reduction in Brazilian women using the Breast-Q® questionnaire: a cross-sectional controlled study.
Clinics, 2018Co-Authors: Adriana Corbolan Andrade, Daniela Francescato Veiga, Yara Juliano, Miguel Sabino-neto, Isabella De Carvalho Aguiar, Lydia Masako FerreiraAbstract:OBJECTIVE The aim of this study was to analyse patient-reported outcomes of reduction mammoplasty among Brazilian women. METHODS A total of 100 women were enrolled in this cross-sectional controlled study, 50 with Breast Hypertrophy (Hypertrophy Group) and 50 who had undergone Breast reduction at least six and up to 12 months before (Mammoplasty Group). The Brazilian version of the Breast-Q® was applied to assess patient-reported outcomes. The module reduction/mastopexy was used, and the preoperative and postoperative versions were applied to the Hypertrophy and mammoplasty groups, respectively. RESULTS The mammoplasty group presented higher scores for the subscales satisfaction with Breasts, psychosocial well-being, sexual well-being and physical well-being (p=0.0001 for all of these subscales). CONCLUSION These results suggest that patients submitted to reduction mammoplasty are satisfied with the outcomes and present better quality of life scores compared with women with Breast Hypertrophy.
-
Breast Hypertrophy, Reduction Mammaplasty, and Body Image.
Aesthetic Surgery Journal, 2018Co-Authors: Cristiane Costa Fonseca, Daniela Francescato Veiga, Edgard Da Silva Garcia, Isaías Vieira Cabral, Monique Maçais De Carvalho, Maria José Azevedo De Brito, Lydia Masako FerreiraAbstract:Background Body image dissatisfaction is one of the major factors that motivate patients to undergo plastic surgery. However, few studies have associated body satisfaction with reduction mammaplasty. Objectives The aim of this study was to evaluate the impact of Breast Hypertrophy and reduction mammaplasty on body image. Methods Breast Hypertrophy patients, with reduction mammaplasty already scheduled between June 2013 and December 2015 (mammaplasty group, MG), were prospectively evaluated through the body dysmorphic disorder examination (BDDE), body investment scale (BIS), and Breast evaluation questionnaire (BEQ55) tools. Women with normal-sized Breasts were also evaluated as study controls (normal-sized Breast group, NSBG). All the participants were interviewed at the initial assessment and after six months. Data were analyzed before and after six months. Results Each group consisted of 103 women. The MG group had a significant improvement in BDDE, BIS, and BEQ55 scores six months postoperatively (P ≤ 0.001 for the three instruments), whereas the NSBG group showed no alteration in results over time (P = 0.876; P = 0.442; and P = 0.184, respectively). In the intergroup comparison it was observed that the MG group began to invest more in the body, similarly to the NSBG group, and surpassed the level of satisfaction and body image that the women of the NSBG group had after the surgery. Conclusions Reduction mammaplasty promoted improvement in body image of women with Breast Hypertrophy. Level of Evidence 2
-
Increased Capacity for Work and Productivity After Breast Reduction
Aesthetic Surgery Journal, 2016Co-Authors: Isaías Vieira Cabral, Edgard Da Silva Garcia, Lydia Masako Ferreira, Joel Veiga-filho, Yara Juliano, Rebecca Neponucena Sobrinho, Natália Lana Larcher Pinto, Daniela Francescato VeigaAbstract:Background: Breast Hypertrophy is a prevalent condition among women worldwide, which can affect different aspects of their quality of life. The physical and emotional impact of Breast Hypertrophy may harm daily activities, including work. Objectives: To assess the impact of reduction mammaplasty on the ability to work and productivity of women with Breast Hypertrophy. Methods: A total of 60 patients with Breast Hypertrophy, already scheduled for Breast reduction, aged 18 to 60 years and who had formal or autonomous employment were prospectively enrolled. The Brazilian versions of two validated tools, Work Productivity and Activity Impairment - General Health (WPAI-GH) and Work Limitations Questionnaire (WLQ) were self-administered at the preoperative evaluation and six months following surgery. Results: The median age was 33 years, median body mass index was 24 kg/m2, and the median total weight of resected Breast tissue was 617.5 g. According to the Brazilian classification of occupation, most patients (53%) had technical, scientific, artistic and similar occupations. There was a significant improvement in work capacity and productivity six months after the reduction mammaplasty, denoted by a decrease in presenteeism, absenteeism, and WLQ Productivity Loss Score (Wilcoxon analysis of variance: P < .0001 for each of these domains). Conclusions: Reduction mammaplasty increases the work capacity and productivity of Brazilian women with Breast Hypertrophy. Level of Evidence: 4 ![Graphic][1] [1]: /embed/inline-graphic-1.gif
-
Sexual Function and Depression Outcomes Among Breast Hypertrophy Patients Undergoing Reduction Mammaplasty: A Randomized Controlled Trial.
Annals of Plastic Surgery, 2016Co-Authors: Flávia N. M. Beraldo, Daniela Francescato Veiga, Edgard Da Silva Garcia, Joel Veiga-filho, Gerusa S. Vilas-bôas, Yara Juliano, Miguel Sabino-neto, Lydia Masako FerreiraAbstract:PURPOSE The Breasts are important symbols of femininity and sensuality. Alterations such as Breast Hypertrophy can affect several aspects of women's quality of life. Breast Hypertrophy is a prevalent health condition, which is treated by reduction mammaplasty. The aim of the present study was to assess sexual function and depression outcomes among Breast Hypertrophy patients undergoing reduction mammaplasty. METHODS Sixty Breast Hypertrophy patients were randomly allocated to a control group (CG) (n = 30) or a Breast reduction group (BRG) (n = 30). The patients in the CG were assessed at the first appointment as well as 3 and 6 months later. The patients in the BRG were assessed preoperatively as well as 3 and 6 months postoperatively. Validated instruments, the Female Sexual Function Index and the Beck Depression Inventory, were used to assess sexual function and depression among the subjects. The results of these assessments were compared within and between groups. RESULTS Twenty-seven and 29 patients in the CG and the BRG, respectively, completed the 6-month follow-up period. At baseline, the groups did not differ significantly with regard to the main demographic data. In the initial assessment, the groups did not differ significantly with regard to Female Sexual Function Index or Beck Depression Inventory scores. Compared with the CG, the BRG reported better sexual function 3 (P = 0.015) and 6 (P = 0.009) months postoperatively. Regarding depression scores, the reduction mammaplasty group had better results 6 months postoperatively (P = 0.014). CONCLUSIONS Reduction mammaplasty positively affected sexual function and depression levels in Breast Hypertrophy patients.
-
The Impact of Surgical Treatment on the Self-Esteem of Patients with Breast Hypertrophy, Hypomastia, or Breast Asymmetry
Aesthetic Plastic Surgery, 2011Co-Authors: Miguel Sabino Neto, Luiz Eduardo Felipe Abla, Ana Lucia Alves Lemos, Elvio Bueno Garcia, Mariana Junqueira Reis Enout, Nádia Canale Cabral, Lydia Masako FerreiraAbstract:Background Currently, the concept of health includes not only the absence of disease but also a complete state of physical, psychological, and social well-being with increased emphasis on the importance of self-esteem. This study aimed to evaluate the impact of surgical treatment on the self-esteem of patients with Breast asymmetry, Breast Hypertrophy, or hypomastia.
Floyd Barry - One of the best experts on this subject based on the ideXlab platform.
-
massive virginal Breast Hypertrophy as a cause of recurrent humoral hypercalcemia due to parathyroid hormone related protein pthrp secretion
Pediatric Research, 1993Co-Authors: Floyd Barry, Felix A Conte, Melvin M GrumbachAbstract:Humoral hypercalcemia associated with certain neoplasms is caused by their secretion of a parathyroid-like 16-18 kd peptide, PTHrP. PTHrP also is expressed by keratinocytes, placenta, fetal parathyroids, and lactating mouse mammary tissue. We report a 15 y old female who presented with massive virginal Breast Hypertrophy and symptoms of urinary frequency, fatigue, and personality changes attributable to hypercalcemia. At 13 1/2 y she had a successful liver transplant for α1-anti-trypsin deficiency. This was followed by rapid Breast growth; 6 months later she had menarche and then regular menses. At 15 y symptomatic hypercalcemia was documented -serum Ca 16 mg/dl, P 2.7 mg/dl, alk phosphatase 151 U/l, PTH 5 pg/ml (n=10-65), and PTHrP 9.4 pmol/L (n=<1.5); 1,25(OH)2D 28 pg/ml (20-76) unlike the usually elevated level with PTH excess. The hypercalcemia responded promptly to saline diuresis. Imaging studies failed to show a parathyroid abnormality or tumor. She had three subsequent episodes of symptomatic hypercalcumin 4 - 5 days prior to menses; PTHrP levels were undetectable between episodes. Following an extensive reduction mammoplasty, the hypercalcemia has not recurred. Studies of PTHrP mRNA in the tissue are in progress. In summary, benign Breast Hypertrophy can cause secretion of PTHrP which results in hypercalcomia. The cyclical occurrence and its temporal relationship to the menstrual cycle suggests that changes in circulating ovarian sex steroids may have affected PTHrP synthesis.
-
MASSIVE VIRGINAL Breast Hypertrophy AS A CAUSE OF RECURRENT HUMORAL HYPERCALCEMIA DUE TO PARATHYROID HORMONE-RELATED PROTEIN (PTHrP) SECRETION
Pediatric Research, 1993Co-Authors: Floyd Barry, Felix A Conte, Melvin M GrumbachAbstract:Humoral hypercalcemia associated with certain neoplasms is caused by their secretion of a parathyroid-like 16-18 kd peptide, PTHrP. PTHrP also is expressed by keratinocytes, placenta, fetal parathyroids, and lactating mouse mammary tissue. We report a 15 y old female who presented with massive virginal Breast Hypertrophy and symptoms of urinary frequency, fatigue, and personality changes attributable to hypercalcemia. At 13 1/2 y she had a successful liver transplant for α1-anti-trypsin deficiency. This was followed by rapid Breast growth; 6 months later she had menarche and then regular menses. At 15 y symptomatic hypercalcemia was documented -serum Ca 16 mg/dl, P 2.7 mg/dl, alk phosphatase 151 U/l, PTH 5 pg/ml (n=10-65), and PTHrP 9.4 pmol/L (n=
Felix A Conte - One of the best experts on this subject based on the ideXlab platform.
-
massive virginal Breast Hypertrophy as a cause of recurrent humoral hypercalcemia due to parathyroid hormone related protein pthrp secretion
Pediatric Research, 1993Co-Authors: Floyd Barry, Felix A Conte, Melvin M GrumbachAbstract:Humoral hypercalcemia associated with certain neoplasms is caused by their secretion of a parathyroid-like 16-18 kd peptide, PTHrP. PTHrP also is expressed by keratinocytes, placenta, fetal parathyroids, and lactating mouse mammary tissue. We report a 15 y old female who presented with massive virginal Breast Hypertrophy and symptoms of urinary frequency, fatigue, and personality changes attributable to hypercalcemia. At 13 1/2 y she had a successful liver transplant for α1-anti-trypsin deficiency. This was followed by rapid Breast growth; 6 months later she had menarche and then regular menses. At 15 y symptomatic hypercalcemia was documented -serum Ca 16 mg/dl, P 2.7 mg/dl, alk phosphatase 151 U/l, PTH 5 pg/ml (n=10-65), and PTHrP 9.4 pmol/L (n=<1.5); 1,25(OH)2D 28 pg/ml (20-76) unlike the usually elevated level with PTH excess. The hypercalcemia responded promptly to saline diuresis. Imaging studies failed to show a parathyroid abnormality or tumor. She had three subsequent episodes of symptomatic hypercalcumin 4 - 5 days prior to menses; PTHrP levels were undetectable between episodes. Following an extensive reduction mammoplasty, the hypercalcemia has not recurred. Studies of PTHrP mRNA in the tissue are in progress. In summary, benign Breast Hypertrophy can cause secretion of PTHrP which results in hypercalcomia. The cyclical occurrence and its temporal relationship to the menstrual cycle suggests that changes in circulating ovarian sex steroids may have affected PTHrP synthesis.
-
MASSIVE VIRGINAL Breast Hypertrophy AS A CAUSE OF RECURRENT HUMORAL HYPERCALCEMIA DUE TO PARATHYROID HORMONE-RELATED PROTEIN (PTHrP) SECRETION
Pediatric Research, 1993Co-Authors: Floyd Barry, Felix A Conte, Melvin M GrumbachAbstract:Humoral hypercalcemia associated with certain neoplasms is caused by their secretion of a parathyroid-like 16-18 kd peptide, PTHrP. PTHrP also is expressed by keratinocytes, placenta, fetal parathyroids, and lactating mouse mammary tissue. We report a 15 y old female who presented with massive virginal Breast Hypertrophy and symptoms of urinary frequency, fatigue, and personality changes attributable to hypercalcemia. At 13 1/2 y she had a successful liver transplant for α1-anti-trypsin deficiency. This was followed by rapid Breast growth; 6 months later she had menarche and then regular menses. At 15 y symptomatic hypercalcemia was documented -serum Ca 16 mg/dl, P 2.7 mg/dl, alk phosphatase 151 U/l, PTH 5 pg/ml (n=10-65), and PTHrP 9.4 pmol/L (n=
Daniela Francescato Veiga - One of the best experts on this subject based on the ideXlab platform.
-
Outcomes analysis of Breast reduction in Brazilian women using the Breast-Q® questionnaire: a cross-sectional controlled study.
Clinics, 2018Co-Authors: Adriana Corbolan Andrade, Daniela Francescato Veiga, Yara Juliano, Miguel Sabino-neto, Isabella De Carvalho Aguiar, Lydia Masako FerreiraAbstract:OBJECTIVE The aim of this study was to analyse patient-reported outcomes of reduction mammoplasty among Brazilian women. METHODS A total of 100 women were enrolled in this cross-sectional controlled study, 50 with Breast Hypertrophy (Hypertrophy Group) and 50 who had undergone Breast reduction at least six and up to 12 months before (Mammoplasty Group). The Brazilian version of the Breast-Q® was applied to assess patient-reported outcomes. The module reduction/mastopexy was used, and the preoperative and postoperative versions were applied to the Hypertrophy and mammoplasty groups, respectively. RESULTS The mammoplasty group presented higher scores for the subscales satisfaction with Breasts, psychosocial well-being, sexual well-being and physical well-being (p=0.0001 for all of these subscales). CONCLUSION These results suggest that patients submitted to reduction mammoplasty are satisfied with the outcomes and present better quality of life scores compared with women with Breast Hypertrophy.
-
Breast Hypertrophy, Reduction Mammaplasty, and Body Image.
Aesthetic Surgery Journal, 2018Co-Authors: Cristiane Costa Fonseca, Daniela Francescato Veiga, Edgard Da Silva Garcia, Isaías Vieira Cabral, Monique Maçais De Carvalho, Maria José Azevedo De Brito, Lydia Masako FerreiraAbstract:Background Body image dissatisfaction is one of the major factors that motivate patients to undergo plastic surgery. However, few studies have associated body satisfaction with reduction mammaplasty. Objectives The aim of this study was to evaluate the impact of Breast Hypertrophy and reduction mammaplasty on body image. Methods Breast Hypertrophy patients, with reduction mammaplasty already scheduled between June 2013 and December 2015 (mammaplasty group, MG), were prospectively evaluated through the body dysmorphic disorder examination (BDDE), body investment scale (BIS), and Breast evaluation questionnaire (BEQ55) tools. Women with normal-sized Breasts were also evaluated as study controls (normal-sized Breast group, NSBG). All the participants were interviewed at the initial assessment and after six months. Data were analyzed before and after six months. Results Each group consisted of 103 women. The MG group had a significant improvement in BDDE, BIS, and BEQ55 scores six months postoperatively (P ≤ 0.001 for the three instruments), whereas the NSBG group showed no alteration in results over time (P = 0.876; P = 0.442; and P = 0.184, respectively). In the intergroup comparison it was observed that the MG group began to invest more in the body, similarly to the NSBG group, and surpassed the level of satisfaction and body image that the women of the NSBG group had after the surgery. Conclusions Reduction mammaplasty promoted improvement in body image of women with Breast Hypertrophy. Level of Evidence 2
-
Increased Capacity for Work and Productivity After Breast Reduction
Aesthetic Surgery Journal, 2016Co-Authors: Isaías Vieira Cabral, Edgard Da Silva Garcia, Lydia Masako Ferreira, Joel Veiga-filho, Yara Juliano, Rebecca Neponucena Sobrinho, Natália Lana Larcher Pinto, Daniela Francescato VeigaAbstract:Background: Breast Hypertrophy is a prevalent condition among women worldwide, which can affect different aspects of their quality of life. The physical and emotional impact of Breast Hypertrophy may harm daily activities, including work. Objectives: To assess the impact of reduction mammaplasty on the ability to work and productivity of women with Breast Hypertrophy. Methods: A total of 60 patients with Breast Hypertrophy, already scheduled for Breast reduction, aged 18 to 60 years and who had formal or autonomous employment were prospectively enrolled. The Brazilian versions of two validated tools, Work Productivity and Activity Impairment - General Health (WPAI-GH) and Work Limitations Questionnaire (WLQ) were self-administered at the preoperative evaluation and six months following surgery. Results: The median age was 33 years, median body mass index was 24 kg/m2, and the median total weight of resected Breast tissue was 617.5 g. According to the Brazilian classification of occupation, most patients (53%) had technical, scientific, artistic and similar occupations. There was a significant improvement in work capacity and productivity six months after the reduction mammaplasty, denoted by a decrease in presenteeism, absenteeism, and WLQ Productivity Loss Score (Wilcoxon analysis of variance: P < .0001 for each of these domains). Conclusions: Reduction mammaplasty increases the work capacity and productivity of Brazilian women with Breast Hypertrophy. Level of Evidence: 4 ![Graphic][1] [1]: /embed/inline-graphic-1.gif
-
Sexual Function and Depression Outcomes Among Breast Hypertrophy Patients Undergoing Reduction Mammaplasty: A Randomized Controlled Trial.
Annals of Plastic Surgery, 2016Co-Authors: Flávia N. M. Beraldo, Daniela Francescato Veiga, Edgard Da Silva Garcia, Joel Veiga-filho, Gerusa S. Vilas-bôas, Yara Juliano, Miguel Sabino-neto, Lydia Masako FerreiraAbstract:PURPOSE The Breasts are important symbols of femininity and sensuality. Alterations such as Breast Hypertrophy can affect several aspects of women's quality of life. Breast Hypertrophy is a prevalent health condition, which is treated by reduction mammaplasty. The aim of the present study was to assess sexual function and depression outcomes among Breast Hypertrophy patients undergoing reduction mammaplasty. METHODS Sixty Breast Hypertrophy patients were randomly allocated to a control group (CG) (n = 30) or a Breast reduction group (BRG) (n = 30). The patients in the CG were assessed at the first appointment as well as 3 and 6 months later. The patients in the BRG were assessed preoperatively as well as 3 and 6 months postoperatively. Validated instruments, the Female Sexual Function Index and the Beck Depression Inventory, were used to assess sexual function and depression among the subjects. The results of these assessments were compared within and between groups. RESULTS Twenty-seven and 29 patients in the CG and the BRG, respectively, completed the 6-month follow-up period. At baseline, the groups did not differ significantly with regard to the main demographic data. In the initial assessment, the groups did not differ significantly with regard to Female Sexual Function Index or Beck Depression Inventory scores. Compared with the CG, the BRG reported better sexual function 3 (P = 0.015) and 6 (P = 0.009) months postoperatively. Regarding depression scores, the reduction mammaplasty group had better results 6 months postoperatively (P = 0.014). CONCLUSIONS Reduction mammaplasty positively affected sexual function and depression levels in Breast Hypertrophy patients.
-
Influência da hipertrofia mamária na capacidade funcional das mulheres
Revista Brasileira De Reumatologia, 2007Co-Authors: Carlos Delano Mundim Araújo, Daniela Francescato Veiga, Heitor Carvalho Gomes, Bernardo Hochman, Paulo Magalhães Fernandes, Neil Ferreira Novo, Lydia Masako FerreiraAbstract:OBJECTIVE: to investigate the influence of Breast Hypertrophy in the musculoskeletal-system through the evaluation of the functional capacity in women. METHOD: 50 women with Breast Hypertrophy were studied and the results were compared to the 50 women without Breast Hypertrophy. The STANFORD HEALTH ASSESSMENT QUESTIONNAIRE 20 (HAQ-20) was applied to assess the functional capacity. It contains 20 questions about daily activities in which the patient has four answer options, which are scored. Lower scores indicate better functional capacity. RESULTS: the mean score in the control group was 0.10, while in the Breast Hypertrophy group it was 0.71. When Mann-Whitney test was run, Hypertrophy group showed statistically higher scores (p < 0.00). CONCLUSION: Breast Hypertrophy patients have more difficulties to perform common activities of the daily life.